Kinapse solution to improve efficiency and
enhance overall sponsor experience with Veeva's next-generation
submission application
Today at the Drug Information Association’s (DIA) Annual
Meeting, Veeva Systems (NYSE: VEEV) and Kinapse Ltd., a leading
provider of life sciences advisory and operational services,
announced that Kinapse has selected Veeva Vault Submissions to
power its new regulatory operational services. Veeva Vault
Submissions provides Kinapse a modern cloud application for
authoring and managing regulatory submissions content. Kinapse will
now offer sponsors the option to produce regulatory deliverables on
Vault Submissions and leverage Kinapse’s new efficient processes
that have been optimized on Veeva’s cloud platform.
“Service providers play an increasing role in regulatory
operations today,” said Katrin Spaepen, director of Vault RIM
Strategy at Veeva Systems. “Veeva Vault Submissions will provide
Kinapse customers a shared authoritative source for submissions
content. Combined with Kinapse’s services, sponsors can achieve
global accessibility and real-time visibility into their regulatory
submissions processes.”
Today there are two ways sponsors work with regulatory
submissions service providers. Sponsors have service providers
access their on-premise systems remotely, slowing performance and
limiting innovation by constraining the service provider to follow
the sponsor’s model of operation. Alternatively, sponsors author,
review, and approve submission documents within their own systems
then manually transmit documents to submission partners. This makes
document changes difficult to track, creating inefficiencies and
increasing risk.
“Veeva Vault Submissions changes how sponsors and their partners
collaborate by providing fast, direct access to manage content and
data,” said Marc Gabriel, client partner at Kinapse. “Veeva Vault
ensures submissions are managed with greater quality, efficiency,
and control by allowing the sponsor and service provider to access
their documents and data through the cloud and view status in
real-time.”
Kinapse is coupling Vault Submissions with a new set of
streamlined regulatory processes that take advantage of Veeva’s
advanced capabilities for regulated document management. Kinapse
rigorously tested the platform’s key functions, including the
segmentation of client data. The Kinapse regulatory team is trained
and ready to deliver submissions on the Vault platform.
“There is significant interest around Veeva’s unique cloud
applications for regulatory information management (RIM),” said
Aileen Fisher, vice president of Regulatory Affairs and
Pharmacovigilance Services for Kinapse. “With Veeva Vault
Submissions, we expect our customers to benefit from greater
access, visibility, and control over their submissions information
and, ultimately, speed their time to submission.”
Kinapse provides the biopharmaceutical industry with services
across the product lifecycle, including submission management,
strategy, publishing, CMC authoring, labeling, intelligence, safety
reports, and full pre- and post-submission support.
Kinapse plans to add other Veeva Vault RIM applications to their
service offerings, including Veeva Vault Registrations and Veeva
Vault SubmissionsArchive.
Additional Information
For more on Veeva Vault Submissions, visit:
veeva.com/eu/VaultSubmissions
Stay updated on the latest Veeva news on LinkedIn:
linkedin.com/company/veeva-systems
Follow @Veeva_EU on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
For more on Kinapse regulatory services, visit:
kinapse.com/our-expertise/our-services/regulatory-affairs/
Stay updated on the latest Kinapse news on LinkedIn:
linkedin.com/company/kinapse
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the
global life sciences industry. Committed to innovation, product
excellence, and customer success, Veeva has more than 400
customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices in Europe, Asia, and Latin
America. For more information, visit veeva.com/eu.
About Kinapse
Kinapse provides expert advisory, capability building and
operational services to the world’s leading life sciences
organizations, their customers, suppliers and regulators. Their
clients include many of the world’s leading pharmaceutical
companies, their customers, suppliers and regulators. Kinapse uses
a novel operating and delivery model that allows them to bring
together the very best people in virtual teams, in a wide range of
R&D domains, committed to the success of our clients.
Headquartered in London, Kinapse currently employs over 600 people
in the U.K., U.S. and India. For more information, please visit
kinapse.com.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva’s products and services,
the results from use of Veeva’s products and services, and general
business conditions, particularly in the life sciences industry.
Any forward-looking statements contained in this press release are
based upon Veeva’s historical performance and its current plans,
estimates, and expectations, and are not a representation that such
plans, estimates, or expectations will be achieved. These
forward-looking statements represent Veeva’s expectations as of the
date of this press announcement. Subsequent events may cause these
expectations to change, and Veeva disclaims any obligation to
update the forward-looking statements in the future. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual results to differ
materially. Additional risks and uncertainties that could affect
Veeva’s financial results are included under the captions, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in the company’s filing on
Form 10-Q for the period ended April 30, 2016. This is
available on the company’s website at veeva.com under the Investors
section and on the SEC’s website at sec.gov. Further information on
potential risks that could affect actual results will be included
in other filings Veeva makes with the SEC from time to time.
###
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160627005798/en/
Veeva Systems Inc.Sue Glanville / Cate
Bonthuyssue@catalystcomms.co.uk / cate@catalystcomms.co.uk+44 (0)
7715 817589 / +44 (0) 7746 546773orKinapseLucy
Ackahlucy.ackah@kinapse.com
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Apr 2023 to Apr 2024